AxioMx MembraneProSelect™ has been launched, a new service that enables the development of recombinant antibodies that recognize the native conformation of cell membrane protein extracellular domains.

“Researchers now have a resource for the development of research-purposed or therapeutic-candidate antibodies that specifically and effectively bind the ECDs of their cell membrane proteins of interest,” said Tom Thompson, vice president of sales and marketing, at AxioMx. “We believe this fills a large, unmet life science marketplace need and it will help scientists to develop better antibodies to an important class of targets that have been difficult to address with traditional animal-based methods.”